Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ?(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
CRYSVITA could offer access to the first biologic treatment for EU patients with TIO who cannot undergo surgical removal of...


















